These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14510908)

  • 1. Effect of dehydroepiandrosterone supplementation on fatty acid and hormone levels in patients with X-linked adrenoleucodystrophy.
    Assies J; Haverkort EB; Lieverse R; Vreken P
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):459-66. PubMed ID: 14510908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women.
    Morales AJ; Haubrich RH; Hwang JY; Asakura H; Yen SS
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):421-32. PubMed ID: 9876338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women.
    Genazzani AR; Pluchino N; Begliuomini S; Stomati M; Bernardi F; Pieri M; Casarosa E; Palumbo M; Genazzani AD; Luisi M
    Gynecol Endocrinol; 2006 Nov; 22(11):627-35. PubMed ID: 17145649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy.
    Kemp S; Valianpour F; Denis S; Ofman R; Sanders RJ; Mooyer P; Barth PG; Wanders RJ
    Mol Genet Metab; 2005 Feb; 84(2):144-51. PubMed ID: 15670720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
    Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dehydroepiandrosterone (DHEA) supplementation on fatty acid and hormone levels in patients with X-linked adrenoleukodystrophy.
    Assies J; Haverkort EB; Lieverse R; Vreken P
    Adv Exp Med Biol; 2003; 544():243-4. PubMed ID: 14713236
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women.
    Genazzani AD; Stomati M; Strucchi C; Puccetti S; Luisi S; Genazzani AR
    Fertil Steril; 2001 Aug; 76(2):241-8. PubMed ID: 11476767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of saturated and polyunsaturated very-long-chain fatty acids in fibroblasts from patients with defects in peroxisomal beta-oxidation.
    Street JM; Singh H; Poulos A
    Biochem J; 1990 Aug; 269(3):671-7. PubMed ID: 2117919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
    Labrie F; Bélanger A; Cusan L; Candas B
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiles of very-long-chain fatty acids in plasma, fibroblasts, and blood cells in Zellweger syndrome, X-linked adrenoleukodystrophy, and rhizomelic chondrodysplasia punctata.
    Schutgens RB; Bouman IW; Nijenhuis AA; Wanders RJ; Frumau ME
    Clin Chem; 1993 Aug; 39(8):1632-7. PubMed ID: 8353949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatty acids and homocysteine levels in patients with recurrent depression: an explorative pilot study.
    Assies J; Lok A; Bockting CL; Weverling GJ; Lieverse R; Visser I; Abeling NG; Duran M; Schene AH
    Prostaglandins Leukot Essent Fatty Acids; 2004 Apr; 70(4):349-56. PubMed ID: 15041026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men.
    Wolf OT; Neumann O; Hellhammer DH; Geiben AC; Strasburger CJ; Dressendörfer RA; Pirke KM; Kirschbaum C
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2363-7. PubMed ID: 9215320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and hormonal effects of oral DHEA in premenopausal women with HIV infection: a randomized, prospective, placebo-controlled pilot study.
    Poretsky L; Song L; Brillon DJ; Ferrando S; Chiu J; McElhiney M; Ferenczi A; Sison C; Haller I; Rabkin J
    Horm Metab Res; 2009 Mar; 41(3):244-9. PubMed ID: 18810712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease.
    Gebre-Medhin G; Husebye ES; Mallmin H; Helström L; Berne C; Karlsson FA; Kämpe O
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):775-80. PubMed ID: 10848883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
    Morales AJ; Nolan JJ; Nelson JC; Yen SS
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1360-7. PubMed ID: 7515387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triacylglycerols and their fatty acid composition in edible Mediterranean molluscs and crustacean.
    Sinanoglou VJ; Meimaroglou D; Miniadis-Meimaroglou S
    Food Chem; 2008 Sep; 110(2):406-13. PubMed ID: 26049233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].
    Rabijewski M; Zgliczyński W
    Endokrynol Pol; 2007; 58(3):213-9. PubMed ID: 17940987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between dehydroepiandrosterone-sulphate and anthropometric, metabolic and hormonal variables in a large cohort of obese women.
    Maccario M; Mazza E; Ramunni J; Oleandri SE; Savio P; Grottoli S; Rossetto R; Procopio M; Gauna C; Ghigo E
    Clin Endocrinol (Oxf); 1999 May; 50(5):595-600. PubMed ID: 10468925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone.
    Wichers-Rother M; Grigull A; Sokolowski P; Stoffel-Wagner B; Köhler W
    J Neurol; 2005 Dec; 252(12):1525-9. PubMed ID: 16362829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose dehydroepiandrosterone affects behavior in hypopituitary androgen-deficient women: a placebo-controlled trial.
    Johannsson G; Burman P; Wirén L; Engström BE; Nilsson AG; Ottosson M; Jonsson B; Bengtsson BA; Karlsson FA
    J Clin Endocrinol Metab; 2002 May; 87(5):2046-52. PubMed ID: 11994339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.